3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
41
Squamous Cell Carcinoma of Head and Neck
22
Lung Neoplasms
22
Oropharyngeal Neoplasms
14
Nasopharyngeal Carcinoma
13
Carcinoma
12
Urinary Bladder Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Head and Neck Neoplasms
8
Mouth Neoplasms
6
Laryngeal Neoplasms
6
Small Cell Lung Carcinoma
5
Neoplasms
5
Hypopharyngeal Neoplasms
5
Cholangiocarcinoma
5
Biliary Tract Neoplasms
5
Stomach Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Lymphoid Interstitial Pneumonia
3
Lung Diseases
3
Carcinoma, Transitional Cell
3
Carcinoma, Squamous Cell
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Interventions
pembrolizumab
1
Pemetrexed
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Cisplatin
×
30 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled